Blocking a Rogue Enzyme in Brain Cells Slows Microglial Aging
A misdirected enzyme called Cathepsin B escapes lysosomes and drives brain cell senescence — and blocking it reverses aging signs in mice.
Summary
As brains age, the immune cells of the brain — microglia — become senescent, turning from protectors into promoters of neurodegeneration. Researchers at Beijing Institute of Technology have identified a key culprit: Cathepsin B, a protein-digesting enzyme normally locked inside lysosomes. In aging mice and lab models, lysosomal membranes become leaky, releasing Cathepsin B into the cell's interior (cytosol), where it remains active and begins degrading a spliceosome protein called SNRPE. This disrupts RNA processing and triggers senescence without killing the cell. Critically, standard Cathepsin B inhibitors — designed for acidic lysosomal conditions — fail to block this effect. Inhibitors that work at neutral pH successfully reduced microglial senescence both in cell culture and in aged mouse brains, opening a plausible drug target for brain aging and neurodegeneration.
Detailed Summary
Brain aging is accompanied by the accumulation of senescent microglia — the brain's resident immune cells — that shift from protective to inflammatory and pro-degenerative roles. Understanding what drives this transition is essential for developing therapies against age-related neurodegeneration, including Alzheimer's disease. This study pinpoints cytosolic Cathepsin B (CatB) as a central mediator of that shift.
Cathepsin B is a lysosomal protease — an enzyme designed to digest proteins inside the acidic compartments of cells. The researchers found that in aged mice and in laboratory senescence models, lysosomal membranes become permeable, releasing CatB into the neutral-pH cytosol, where it retains enzymatic activity rather than becoming inactivated. This compartment escape turns CatB into an unregulated destructive agent within the cell body.
Once in the cytosol, CatB was found to bind and degrade SNRPE, a core component of the spliceosome — the molecular machine that processes RNA transcripts. Disruption of SNRPE induces classic senescence-associated phenotypes without triggering outright cell death, meaning affected microglia persist in a dysfunctional, inflammatory state rather than being cleared.
A critical translational insight from this work is that conventional CatB inhibitors, optimized for the acidic lysosomal environment, are ineffective against cytosolic CatB. In contrast, inhibitors active at neutral pH successfully suppressed microglial senescence in both cell-based experiments and in aged mouse brains. This distinction matters enormously for drug development: the relevant drug target is cytosolic, not lysosomal.
The findings suggest two therapeutic strategies: stabilizing SNRPE to protect spliceosome integrity, or developing compartment-specific CatB inhibitors that act in the neutral cytosol. Both approaches represent novel angles for combating brain aging and neurodegeneration. Limitations include the study being conducted in mice and cell models, with no human data yet reported, and this summary is based on the abstract only.
Key Findings
- Cathepsin B leaks from lysosomes into the cytosol in aging microglia and remains active at neutral pH.
- Cytosolic Cathepsin B degrades SNRPE, a spliceosome protein, triggering senescence without cell death.
- Standard Cathepsin B inhibitors fail against the cytosolic form; neutral-pH-active inhibitors are required.
- Neutral pH-active CatB inhibitors reduced microglial senescence in aged mouse brains in vivo.
- SNRPE stabilization is proposed as an alternative therapeutic strategy to counter brain aging.
Methodology
The study used aged mice alongside chemically induced senescence models in cultured microglia to characterize cytosolic Cathepsin B activity. Recombinant CatB was delivered directly into the cytosol to confirm its senescence-promoting role. Both conventional acidic-active and novel neutral-pH-active CatB inhibitors were tested in vitro and in aged mouse brains.
Study Limitations
All experiments were performed in mice and in vitro cell models; no human data are reported. The downstream consequences of sustained SNRPE degradation on broader brain function were not detailed in the abstract. This summary is based on the abstract only, as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: